Global Chronic Ocular Surface Pain Market Size study, By Drug Class (Antibiotics, Nonsteroidal Anti-Inflammatory (NSAID), Corticosteroids, Others), By Application (Sinusitis, Migraines, Glaucoma, Others), By End-Users (Hospitals, Specialty Clinics, Homeca

Global Chronic Ocular Surface Pain Market Size study, By Drug Class (Antibiotics, Nonsteroidal Anti-Inflammatory (NSAID), Corticosteroids, Others), By Application (Sinusitis, Migraines, Glaucoma, Others), By End-Users (Hospitals, Specialty Clinics, Homecare, Others), and Regional Forecasts 2022-2028

Global Chronic Ocular Surface Pain Market is valued at approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. Chronic Ocular Surface Pain is a condition that occurs due to the damage of tissue at the ocular surface or from variations to central or peripheral nerves in the ocular surface sensory pathway. The rising prevalence of bacterial and viral ocular infections, increasing geriatric populations, and growing incidences of dry eyes among people, coupled with the rise in healthcare expenditure are several factors fostering the market demand across the globe. For instance, according to the World Health Organization (WHO), the geriatric population around the world is estimated to be over 524 million in 2010, and it is projected to increase to nearly 2 billion by 2050. Consequentially, aged people are more prone to suffer from various eye disorders, which, in turn, augment the market growth across the globe. However, the shortage of skilled professionals and the unavailability of advanced healthcare facilities in developing economies impede the growth of the market over the forecast period of 2022-2028. Also, a rise in the number of research and development activities and increasing drug approvals and launches are anticipated to act as catalyzing factors for the market demand during the forecast period.

The key regions considered for the global Chronic Ocular Surface Pain Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the increasing technological developments in diagnostic procedures and growing healthcare expenditure. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the rising prevalence of ocular diseases, as well as, rising presence of major generic manufacturers, would create lucrative growth prospects for the Chronic Ocular Surface Pain Market across the Asia-Pacific region.

Major market players included in this report are:
Pfizer Inc.
Novartis AG
Zydus Cadila
AstraZeneca
Johnson & Johnson
Bayer AG
Sun Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Company
Eli Lilly and Company
LEO Pharma A/S

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
Antibiotics
Nonsteroidal Anti-Inflammatory (NSAID)
Corticosteroids
Others
By Application:
Sinusitis
Migraines
Glaucoma
Others
By End-Users:
Hospitals
Specialty Clinics
Homecare
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Chronic Ocular Surface Pain Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Pfizer Inc.
Novartis AG
Zydus Cadila
AstraZeneca
Johnson & Johnson
Bayer AG
Sun Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Company
Eli Lilly and Company
LEO Pharma A/S

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.